Laser Treatment of Acne Scars in Fitzpatrick Skin Types III-VI

Cynosure

Status

Completed

Conditions

Acne Scars

Treatments

Device: RevLite Q-Switched Nd:YAG Laser

Study type

Interventional

Funder types

Industry

Identifiers

NCT01221922

C67-10-A

Details and patient eligibility

About

The purpose of this study is to evaluate the RevLite Q-Switched Neodymium: Yttrium-Aluminum-Garnet (Nd:YAG) Laser in the treatment of acne scars in darker skin types (Fitzpatrick Skin Types III, IV, V and VI).

Enrollment

20 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

18 years or older with Fitzpatrick Skin Type III, IV, V or VI
Evidence of atrophic scarring

Exclusion criteria

Pregnancy, lactating or planning to become pregnant during the study
History of cutaneous photosensitization, porphyria, and hypersensitivity to porphyrins or photodermatosis
Any skin pathology or condition that could interfere with the evaluation or requires the use of interfering topical or systemic therapy
Any condition which, in the investigator's opinion, would make it unsafe for the subject to participate
Currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within 30 days prior to entering the study
Subject is unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function
Subject may be unreliable for the study. This includes subjects who engage in excessive alcohol intake or drug abuse, or subjects who are unable to return for scheduled follow-up visits
Use of oral or topical isotretinoin therapy within 6 months prior to enrollment. With the exception of isotretinoin, subjects will be allowed to continue their topical or oral acne medications during the trial
Need to be exposed to artificial tanning devices or excessive sunlight during the trial
Prior treatment with parenteral gold therapy
Diabetes Type I or II, Lupus, Scleroderma or a similar immune system disorder
Subject does not agree to refrain from any other type of facial skin resurfacing (e.g., microdermabrasion, laser or IPL treatment, chemical peel) or injected filler/other substances (e.g., Restylane, Botox) that might affect the treatment area for the duration of the study
Underlying silicone or other nonabsorbable fillers in the treatment area or has had filler (e.g., collagen, fat) injections within the past 3 months
History of keloidal scarring or nodulocystic acne
Phenol or chemical peel or dermabrasion to the the treatment area within the past 6 months